Tuesday March 30, 11:07 am Eastern Time
Company Press Release
Axiom Biotechnologies Appoints Kevin Mullane,
Ph.D. As Executive Vice President, Research
SAN DIEGO--(BW HealthWire)--March 30, 1999--Axiom Biotechnologies Inc. today
announced that it has appointed Kevin Mullane, Ph.D. to the post of executive vice
president, research.
Dr. Mullane, who has more than 20 years of pharmaceutical and biotechnology research
experience, joins Axiom from Chugai Biopharmaceuticals Inc. where he was senior vice president, research and development.
''We are very pleased to have Kevin join the Axiom management team,'' said Stephen Eisold, Axiom's chief executive officer.
''His 22 years of proven experience in the pharmaceutical and biotechnology industries will provide Axiom with a seasoned
manager of internal programs and collaborative research alliances, and a senior scientist with an extensive technical skillset in
drug discovery, lead characterization, pharmacological evaluation and pre-clinical development.''
As Senior Vice President, research and development at Chugai Biopharmaceuticals Inc. (CBI) Dr. Mullane was responsible for
overseeing strategic R&D directions and implementing a comprehensive drug discovery technology program consisting of high
throughput screening, combinatorial chemistry, genomics and bioinformatics platforms. He was also a member of the CBI
Board of Directors.
Prior to joining CBI, Dr. Mullane spent seven years at Gensia Inc., where he achieved the level of divisional vice president,
pharmacology. while at Gensia he was integrally involved with managing research, fundraising and a variety of business
development activities, including closing strategic alliances with Marion Merrill Dow and Pfizer Pharmaceuticals. He also was
directly involved in the introduction of five new drugs into human clinical trials.
Prior to joining Gensia, Dr. Mullane served as director of cardiovascular research at Ciba-Geigy and as research scientist at
Wellcome Research Laboratories. He also served for five years as Associate Professor at New York Medical College,
department of Pharmacology.
Dr. Mullane received his Doctor of Philosophy (Ph.D.) in pharmacology from University of London and his Bachelors of
Science Degree in pharmacology from Chelsea College, University of London.
Axiom Biotechnologies is a privately-held biotechnology company focused on improving the efficiency of drug discovery by
accelerating the process of evolving screening ''hits'' to pre-clinical leads by applying an array of proprietary ''hits''-to-leads
technologies and assays.
The company's patented flagship technology, the High Throughput Pharmacology System (HT-PS(TM)), combines proprietary
natural cell-based assays, high throughput automated instrumentation and novel pharmacoinformatics and biomining tools to
assess and prioritize potential lead compounds based on their functional pharmacological properties.
Through collaborations with major pharmaceutical companies, Axiom is committed to becoming the pharmaceutical industry's
partner of choice in high throughput pharmacology.
Contact:
Axiom Biotechnologies Inc.
Jim Linton, 619/455-4500
www.axiombio.com |
